<DOC>
	<DOCNO>NCT01474187</DOCNO>
	<brief_summary>Irinotecan one effective drug colorectal cancer . In neoadjuvant chemoradiotherapy ( CRT ) , Irinotecan prescribe low dose 50mg/m2/week toxicity . Some current study show irinotecan 's dose increase significantly patient 6/6 6/7 genotype UGT1A1 . therefore , investigator design trial explore maximal tolerable dose ( MTD ) Irinotecan combine neoadjuvant CRT .</brief_summary>
	<brief_title>Genotype-driven Phase I Study Irinotecan Administered Neoadjuvant Chemoradiotherapy Patients With Stage II/III Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients rectal adenocarcinoma Clinical stag T3/4 nodepositive disease Age 1875 year Karnofsky Performance Status &gt; 80 Adequate bone marrow reserve , renal hepatic function Without previous antitumoural chemotherapy No evidence metastatic disease Written inform consent randomization UGT1A1 's genotype 6/6 6/7 Clinical stag I IV Age &lt; 18 &gt; 75 year Karnofsky Performance Status &lt; 80 Previous pelvis radiotherapy Previous antitumoural chemotherapy Clinically significant internal disease Refuse write inform consent randomization UGT1A1 's genotype 7/7</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>phase I study</keyword>
	<keyword>irinotecan</keyword>
</DOC>